Core Viewpoint - The establishment of a joint venture in Hong Kong focused on anti-aging products and solutions, with a registered capital of HKD 50 million, is a strategic move for the company and its partners [1][2]. Group 1: Joint Venture Details - The joint venture agreement was signed on October 27, 2025, among the company and its partners, with ownership stakes of 75%, 20%, and 5% respectively [1]. - The joint venture aims to invest in and operate research and sales of anti-aging products and solutions in Hong Kong and selected Asia-Pacific countries [1]. Group 2: Partner Profiles - Partner I, NAGAWA Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company focused on the development, manufacturing, and commercialization of high-quality drugs, particularly in anti-aging technologies [1]. - Partner II, Mirxes Pte Ltd., is a Singapore-based biotech company specializing in molecular diagnostics, particularly in oncology, and has extensive collaborations with academic institutions for large-scale research [2]. - Mirxes operates two research laboratories, one clinical diagnostic laboratory, one testing laboratory, and two production facilities [2].

Core Viewpoint - The establishment of a joint venture in Hong Kong focused on anti-aging products and solutions, with a registered capital of HKD 50 million, is a strategic move to leverage expertise in biotechnology and pharmaceuticals for growth in the Asia-Pacific market [1][2]. Group 1: Joint Venture Details - The joint venture agreement was signed on October 27, 2025, among the company and its partners, with ownership stakes of 75%, 20%, and 5% respectively [1]. - The joint venture aims to invest in and operate research and sales of anti-aging products and solutions in Hong Kong and selected Asia-Pacific countries [1]. Group 2: Partner Profiles - Partner I, NAGAWA Pharmaceutical Co., Ltd., is a Japanese pharmaceutical company focused on the development, manufacturing, and commercialization of high-quality drugs, particularly in anti-aging technologies [1]. - Partner II, Mirxes Pte Ltd., is a Singapore-based biotechnology company specializing in molecular diagnostics, particularly in oncology, and has extensive collaborations with academic institutions for research [2]. - Mirxes operates two research laboratories, one clinical diagnostic laboratory, one testing laboratory, and two production facilities, showcasing its capacity for innovation and development in the biotechnology sector [2].

Core Viewpoint - The company has entered into a joint venture agreement with NAGAWA Pharmaceutical Co., Ltd and Mirxes Pte Ltd to establish a new company in Hong Kong, focusing on anti-aging products and solutions [1] Group 1: Joint Venture Details - The joint venture will have a registered capital of HKD 50 million, with the company holding 75% ownership, NAGAWA Pharmaceutical 20%, and Mirxes Pte Ltd 5% [1] - The new company aims to invest in and operate research and sales of anti-aging products in Hong Kong and selected Asia-Pacific countries [1] Group 2: Strategic Objectives - This collaboration addresses the changing consumer demands for "healthy lifespan" and "beauty lifespan," enhancing customer lifetime value and loyalty [1] - The initiative marks a shift from providing external beauty services to offering comprehensive beauty and health solutions [1] - The venture is expected to create significant cross-selling opportunities, improve the company's brand image, establish a competitive advantage in the medical anti-aging sector, and ultimately generate sustainable revenue streams for long-term shareholder value [1]